# US 8,280,711 B2 · Sequence based engineering and optimization of single chain antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,280,711 B2
- Document ID: US8280711B2
- Status: Granted
- Kind: B2
- Application number: 12/530,756
- Filed: 2008-03-12
- Published: 2010-06-03
- Granted: 2012-10-02
- Earliest claimed: 2007-03-12
- Assignees: ESBATech, an Alcon Biomedical Research Unit LLC
- Inventors: David M. Urech; Leonardo Borras
- Web page: https://patentgrep.com/patent/US8280711B2

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of single chain antibodies (scFvs), including stability, solubility, and antigen binding affinity. These methods and strategies can be used individually or in combination. The methods of the present invention also include the use of a database comprising scFv sequences from an experimentally screened scFv library of antibodies that have been selected to have superior solubility and stability. The invention also provides methods of using the properties found for these selected antibodies in a general approach for reshaping scFv antibodies to improve stability and solubility properties of a single chain antibody fragment.

## Claims

### Claim 1

A method of identifying one or more framework amino acid positions for mutation in a single chain antibody (scFv), the scFv having VH and VL amino acid sequences, the method comprising:
a) providing a first database of VH, VL, or VH and VL amino acid sequences, the database being stored in a searchable, fixed medium stored on a computer;
b) providing a second database of scFv antibody VH, VL, or VH and VL amino acid sequences selected as having at least one desirable functional property, the database being stored in a searchable, fixed medium stored on a computer;
c) determining amino acid variability at each framework position of the first database and at each framework position of the second database;
d) identifying one or more framework positions at which degree of amino acid variability differs between the first database and the second database to thereby identify one or more framework amino acid positions for mutation in a single chain antibody (scFv).

### Claim 2 (depends on 1)

The method of claim 1, wherein the first database comprises germline VH, VL, or VH and VL amino acid sequences.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first database consists of germline VH, VL, or VH and VL amino acid sequences.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first database comprises mature VH, VL, or VH and VL amino acid sequences.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first database consists of mature VH, VL, or VH and VL amino acid sequences.

### Claim 6 (depends on 4)

The method of claim 4, wherein the mature VH, VL, or VH and VL amino acid sequences are from the Kabat database (KDB).

### Claim 7 (depends on 1)

The method of claim 1, wherein the second database comprises scFv antibody VH, VL, or VH and VL amino acid sequences selected from a QC assay.

### Claim 8 (depends on 2)

The method of claim 2, wherein the second database consists of scFv antibody VH, VL, or VH and VL amino acid sequences selected from a QC assay.

### Claim 9 (depends on 2)

The method of claim 2, wherein the desirable functional property is improved stability, improved solubility, non-aggregation or an improvement in expression.

### Claim 10 (depends on 9)

The method of claim 9, wherein the improvement in expression is observed in a prokaryotic cell.

### Claim 11 (depends on 2)

The method of claim 2, with the proviso that the desirable functional property is not an improvement in antigen binding affinity.

### Claim 12 (depends on 2)

The method of claim 2, wherein the amino acid variability at each framework position is determined by assigning a degree of conservation using Simpson's Index.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more framework amino acid positions is identified for mutation based on the one or more framework amino acid positions having a lower Simpson's Index value in the scFv database as compared to the first database.

### Claim 14 (depends on 12)

The method of claim 12, wherein the one or more framework amino acid positions is identified for mutation based on the one or more framework amino acid positions having a higher Simpson's Index value in the scFv database as compared to the first database.
